{"id":2570,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"1991-05-17","marketCap":7585.37109375,"name":"Ionis Pharmaceuticals Inc","phone":"17609319200","outstanding":143.47000122070312,"symbol":"IONS","website":"https://www.ionispharma.com/","industry":"Biotechnology"},"price":52.4751,"year":2024,"month":1,"day":3,"weekday":"Wednesday","title":"Potential Benefits and Drawbacks of Holding Ionis Pharmaceuticals Inc Stock for the Long Term","date":"2024-01-03","url":"/posts/2024/01/03/IONS","content":[{"section":"Benefits","text":"1. Strong drug pipeline: Ionis Pharmaceuticals has a robust pipeline of RNA-targeted drugs, which have the potential to treat various diseases. The company has several drugs in different stages of development, offering the potential for future revenue growth."},{"section":"Benefits","text":"2. Successful commercialization: Ionis Pharmaceuticals has a track record of successfully commercializing its drugs. The company has partnered with larger pharmaceutical companies for the marketing and distribution of some of its products, which can lead to increased sales and profitability."},{"section":"Benefits","text":"3. Potential for breakthrough treatments: Ionis Pharmaceuticals' RNA-targeted therapies have the potential to revolutionize the treatment of genetic diseases. If the company's drugs prove to be effective in clinical trials and gain regulatory approval, it could significantly impact the healthcare industry and generate substantial returns for long-term investors."},{"section":"Drawbacks","text":"1. Regulatory risks: The pharmaceutical industry is heavily regulated, and Ionis Pharmaceuticals' drug candidates may face challenges in gaining regulatory approval. Delays or failures in obtaining approvals could have a negative impact on the stock's performance."},{"section":"Drawbacks","text":"2. Intense competition: The biotechnology sector is highly competitive, with many companies vying for market share. Ionis Pharmaceuticals competes with both established pharmaceutical companies and emerging biotech firms. Intense competition can impact the company's ability to successfully market its products and maintain profitability."},{"section":"Drawbacks","text":"3. Financial risks: Like most biotech companies, Ionis Pharmaceuticals carries financial risks. The company's revenue is dependent on successful drug development and commercialization. If the company experiences setbacks in clinical trials or struggles to generate sales, it could negatively affect its financial performance and stock value."},{"section":"Drawbacks","text":"4. Volatility: Biotech stocks, including Ionis Pharmaceuticals, can be highly volatile. The stock may experience significant price fluctuations based on news about clinical trials, regulatory approvals, or market sentiment. This volatility can be challenging for long-term investors looking for predictable returns."}],"tags":["LongSignals","Long","Biotechnology"],"news":[{"category":"company","date":1704195540,"headline":"10 Health Care Stocks Whale Activity In Today's Session","id":124808253,"image":"","symbol":"IONS","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3281374208"},{"category":"company","date":1704195420,"headline":"Bank of America more favorable on SMID-cap biotechs into 2024","id":124808257,"image":"","symbol":"IONS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3281371405"},{"category":"company","date":1704190740,"headline":"The Smid-cap biotech stocks to own in 2024, according to Bernstein","id":124808254,"image":"","symbol":"IONS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3281281313"},{"category":"company","date":1704174300,"headline":"Ionis Pharmaceuticals just upgraded at BofA, here's why","id":124816996,"image":"","symbol":"IONS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3281005177"},{"category":"company","date":1704173280,"headline":"Ionis Pharmaceuticals price target raised by $6 at Bernstein, here's why","id":124816997,"image":"","symbol":"IONS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3280990948"},{"category":"company","date":1704165420,"headline":"Ionis shares climb 5% after BofA upgrades stock to buy","id":124816998,"image":"","symbol":"IONS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3281640317"},{"category":"company","date":1703937720,"headline":"EVP CLO \u0026 General Counsel Patrick O'Neil Sells 20,825 Shares of Ionis Pharmaceuticals Inc","id":124780367,"image":"","symbol":"IONS","publisher":"GuruFocus","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3277959162"},{"category":"company","date":1703859139,"headline":"3 Biotech Bull Cases To Consider In 2024 - And 2 Wildcard Recommendations","id":124768111,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1498394529/image_1498394529.jpg?io=getty-c-w1536","symbol":"IONS","publisher":"SeekingAlpha","summary":"The biotech sector is finishing 2023 on a high after a difficult couple of years, buoyed by Big Pharma M\u0026A activity. Explore more details here.","url":"https://seekingalpha.com/article/4660372-3-biotech-bull-cases-to-consider-2024-2-wildcard-recommendations"},{"category":"company","date":1703734441,"headline":"3 Stocks to Buy Now Before They Become Tomorrow’s Trillion-Dollar Companies","id":124821131,"image":"https://media.zenfs.com/en/investorplace_417/7d37ce51594a8ac6f9d728830980b24e","symbol":"IONS","publisher":"Yahoo","summary":"There’s a good reason to consider the best stocks to buy in 2024. The future of the U.S. economy remains uncertain, with conflicting predictions about the possibility of a recession. While some experts anticipate a soft landing, others predict a mild recession starting in the second quarter. Rising inflation and the Federal Reserve’s interest rate hikes contribute to economic uncertainty, and concerns persist about layoffs and financial challenges for individuals. With this unpredictable outlook","url":"https://finance.yahoo.com/news/3-stocks-buy-now-become-033401157.html"},{"category":"company","date":1703433673,"headline":"Ionis Pharmaceuticals Inc EVP, Chief Scientific Officer C Bennett Sells 22,613 Shares","id":124700536,"image":"https://media.zenfs.com/en/us.finance.gurufocus/501923f99a5941556e98b56238850869","symbol":"IONS","publisher":"Yahoo","summary":"Ionis Pharmaceuticals Inc (NASDAQ:IONS), a leader in RNA-targeted drug discovery and development, has experienced a recent insider sell according to a SEC Filing.","url":"https://finance.yahoo.com/news/ionis-pharmaceuticals-inc-evp-chief-160113457.html"},{"category":"company","date":1703243220,"headline":"Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential","id":124671326,"image":"","symbol":"IONS","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3269135503"},{"category":"company","date":1703242020,"headline":"FDA approves AstraZeneca, Ionis drug for ATTRv-PN","id":124671327,"image":"","symbol":"IONS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3269113295"},{"category":"company","date":1703233740,"headline":"Leerink says Wainua approval already baked into Ionis' stock price","id":124678095,"image":"","symbol":"IONS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3268963060"},{"category":"company","date":1703230200,"headline":"S\u0026P 500 Futures Flat in Premarket Trading; Karuna Therapeutics, Ansys Lead","id":124686944,"image":"https://s.wsj.net/public/resources/MWimages/MW-HA919_barron_NS_20181226134502.png","symbol":"IONS","publisher":"MarketWatch","summary":"With U.S. stock markets set to open in two hours, (KRTX) was up 49.8% in pre-market trading, and (ANSS) was up 16.7%. (IONS), (ONTO), and (WMS) were all...","url":"https://www.marketwatch.com/articles/s-p-500-futures-flat-in-premarket-trading-karuna-therapeutics-ansys-lead-ce715c83"},{"category":"company","date":1703228460,"headline":"Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Regeneron (REGN)","id":124673800,"image":"","symbol":"IONS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3268876239"},{"category":"company","date":1703227140,"headline":"William Blair sees ATTR-PN market as large enough for two players","id":124671331,"image":"","symbol":"IONS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3268855090"},{"category":"company","date":1703226060,"headline":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), Ionis Pharmaceuticals (IONS) and Glaukos (GKOS)","id":124675360,"image":"","symbol":"IONS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3268839341"},{"category":"company","date":1703224620,"headline":"Ionis Pharmaceuticals (IONS) Secures Buy Rating on Wainua’s FDA Approval and Strong Market Potential","id":124678099,"image":"","symbol":"IONS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3268817709"},{"category":"company","date":1703221860,"headline":"Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Stryker (SYK)","id":124675832,"image":"","symbol":"IONS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3268778999"},{"category":"company","date":1703221260,"headline":"Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Alnylam Pharma (ALNY)","id":124675361,"image":"","symbol":"IONS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3268771724"},{"category":"company","date":1703216820,"headline":"AstraZeneca, Ionis get US FDA nod for Wainua in \"important milestone\"","id":124671333,"image":"","symbol":"IONS","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=9oh28bw03a"},{"category":"company","date":1703213400,"headline":"LONDON BRIEFING: UK on brink of recession as economy contracts in Q3","id":124671082,"image":"","symbol":"IONS","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=gzn7cie65z"},{"category":"company","date":1703212860,"headline":"Ionis Stock (NASDAQ:IONS) Advances as FDA Approves its Nerve Drug","id":124671336,"image":"","symbol":"IONS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3268660820"},{"category":"company","date":1703202900,"headline":"WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis","id":124651251,"image":"https://media.zenfs.com/en/prnewswire.com/1132adb875f3cd6d354ec9d8296c8f0a","symbol":"IONS","publisher":"Yahoo","summary":"Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved Ionis and AstraZeneca's WAINUA™ (eplontersen) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, commonly referred to as hATTR-PN or ATTRv-PN. WAINUA is the only approved medicine for the treatment of ATTRv-PN that can be self-administered via an auto-injector.","url":"https://finance.yahoo.com/news/wainua-eplontersen-granted-regulatory-approval-235500958.html"},{"category":"company","date":1703198753,"headline":"UPDATE 2-US FDA approves Ionis-AstraZeneca's nerve disease drug","id":124646453,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"IONS","publisher":"Yahoo","summary":"The U.S. Food and Drug Administration (FDA) on Thursday approved Ionis Pharmaceuticals and partner AstraZeneca's drug to treat nerve damage caused by a life-shortening rare disease.  The drug, branded as Wainua, is approved for patients with polyneuropathy, or nerve damage caused by hereditary transthyretin amyloidosis (ATTR-PN), which affects an estimated 40,000 patients globally.  Transthyretin amyloidosis is a progressive condition characterized by the build-up of abnormal protein deposits in the body's organs and tissues.","url":"https://finance.yahoo.com/news/1-us-fda-approves-ionis-224553351.html"},{"category":"company","date":1703186643,"headline":"Ionis Pharmaceuticals, AstraZeneca Get FDA Approval for Rare Genetic Disease Treatment","id":124646956,"image":"","symbol":"IONS","publisher":"Finnhub","summary":"By Ben Glickman Ionis Pharmaceuticals and AstraZeneca's Wainua has been approved by the U.S. Food and Drug Administration for treating a symptom of a rare genetic disease. The FDA approved...","url":"https://finnhub.io/api/news?id=c36e219fa10e056b29922844ddbc7dd6dd084e94232275040c6cddcc5538bfe1"},{"category":"company","date":1703185680,"headline":"Ionis, AstraZeneca get FDA approval for rare genetic disease treatment","id":124659410,"image":"https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png","symbol":"IONS","publisher":"MarketWatch","summary":"Ionis Pharmaceuticals and AstraZeneca's Wainua has been approved by the U.S. Food and Drug Administration for treating a symptom of a rare genetic disease.","url":"https://www.marketwatch.com/story/ionis-pharmaceuticals-astrazeneca-get-fda-approval-for-rare-genetic-disease-treatment-dcd69dbd"},{"category":"company","date":1703162460,"headline":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (IONS), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Arcellx Inc (ACLX)","id":124639727,"image":"","symbol":"IONS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3266943399"},{"category":"company","date":1703139900,"headline":"AstraZeneca / Ionis' Wainua approved in U.S. for treatment of polyneuropathy","id":124671339,"image":"","symbol":"IONS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3268105780"},{"category":"company","date":1703138220,"headline":"Ionis' Wainua granted regulatory approval in U.S. for treatment of hATTR-PN","id":124678108,"image":"","symbol":"IONS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3268066486"},{"category":"company","date":1703098225,"headline":"12 Most Promising Gene Editing Stocks According to Hedge Funds","id":124635625,"image":"https://s.yimg.com/ny/api/res/1.2/pJAS1ny0FNd.TbdavoBDxw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/547b435b1958f9825fdc2bf383bc525a","symbol":"IONS","publisher":"Yahoo","summary":"In this piece, we will take a look at the 12 most promising gene editing stocks according to hedge funds. If you want to skip our take on how the gene editing industry sits right at the top of the global innovation food chain, then you can take a look at the 5 Most Promising […]","url":"https://finance.yahoo.com/news/12-most-promising-gene-editing-185025787.html"},{"category":"company","date":1703073900,"headline":"Ionis to present at 42nd Annual J.P. Morgan Healthcare Conference","id":124632133,"image":"","symbol":"IONS","publisher":"Yahoo","summary":"Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference at 3:00 p.m. PT on Wednesday, January 10, 2024.","url":"https://finance.yahoo.com/news/ionis-present-42nd-annual-j-120500849.html"}]}